Sugi Predict

Sugi Predict / Compounds / SCHEMBL25315840

SCHEMBL25315840

SCHEMBL25315840

Cc1ccc(S(=O)(=O)OCCOc2cc(C(F)(F)F)c3c(cnn3C3CC(C)(O)C3)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ SCN9A Q15858 2/20 0.34
▸ MMP1 P03956 2/20 0.33
▸ MMP13 P45452 2/20 0.33
▸ ADAM17 P78536 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.32
▸ CD4 P01730 2/20 0.31
▸ RIPK1 Q13546 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ PKM P14618 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ KMT2A Q03164 1/20 0.30
▸ HSD11B1 P28845 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26023966 1.00 CA12 (0.38) CA12CA1CA9SCN9AMMP1
SCHEMBL26023953 0.82 ACACB (0.33) SCN9AMAPTALDH1A1KMT2A
SCHEMBL31349573 0.81 AR (0.32) SCN9A
SCHEMBL26030211 0.81 SCN9A (0.33) SCN9AMAPTALDH1A1LMNAKMT2A
SCHEMBL25905002 0.80 PDK2 (0.34) SCN9A
SCHEMBL25904918 0.80 PDK2 (0.34) SCN9A
SCHEMBL25905093 0.80 PDK2 (0.34) SCN9A
SCHEMBL26042301 0.80 AR (0.31) SCN9A
SCHEMBL30506717 0.73 AR (0.33) MAPTALDH1A1LMNAPKMHTT
SCHEMBL26022450 0.73 MAP3K12 (0.32) RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 — — EP disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR CA12 4408/4885CA1 4178/4885CA9 4706/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 CA12 4394/4885CA1 4256/4885CA9 4687/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR CA12 4408/4885CA1 4178/4885CA9 4706/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 CA12 4394/4885CA1 4256/4885CA9 4687/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 CA12 4394/4885CA1 4256/4885CA9 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.